MRTX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (22 Jan 2024 @ 16:00):

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States...

Stats
Today's Volume	20.96M
Average Volume	1.78M
Market Cap	4.12B
EPS	$0 ( 2024-02-27 )
Next earnings date	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.82
ATR14	$0.485 (0.83%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-23	Boxer Capital, Llc	Sell	30 518	Common Stock
2024-01-23	Boxer Capital, Llc	Sell	1 413 475	Warrant (right to purchase)
2024-01-23	Sharp Shalini	Sell	4 162	Common Stock
2024-01-23	Sharp Shalini	Sell	5 252	Common Stock
2024-01-23	Sharp Shalini	Sell	6 808	Common Stock

INSIDER POWER
-93.84
Last 100 transactions
Buy: 125 442 \| Sell: 3 801 194

Volume Correlation

Long: 0.17 (neutral)

Short: -0.56 (weak negative)

Signal:(56.142) Neutral

Mirati Therapeutics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mirati Therapeutics Inc Correlation - Currency/Commodity

0.76
( moderate )

0.87
( strong )

0.84
( strong )

-0.32
( neutral )

-0.39
( neutral )

-0.74
( moderate negative )

Mirati Therapeutics Inc Financials

Annual	2022
Revenue:	$12.44M
Gross Profit:	$11.84M (95.18 %)
EPS:	$-13.18

Q3	2023
Revenue:	$16.40M
Gross Profit:	$14.97M (91.29 %)
EPS:	$-2.49

Q2	2023
Revenue:	$13.69M
Gross Profit:	$12.41M (90.63 %)
EPS:	$-3.04

Q1	2023
Revenue:	$7.17M
Gross Profit:	$6.35M (88.60 %)
EPS:	$-3.02

Financial Reports:

No articles found.

Mirati Therapeutics Inc

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.